InvestorsHub Logo
Followers 33
Posts 2837
Boards Moderated 2
Alias Born 10/24/2015

Re: alexander77 post# 304884

Saturday, 09/05/2020 8:55:06 AM

Saturday, September 05, 2020 8:55:06 AM

Post# of 700288
They have a 5-year deal with Lyell [1], and testing their NY-ESO-1 TCR-T cell product with either a CD8a [2] or dnTGFßRII [2].

Ref
1 https://www.gsk.com/en-gb/media/press-releases/gsk-and-lyell-immunopharma-join-forces-to-develop-the-next-generation-of-cancer-cell-therapies/
2 (ADAP has helped with some of the R&D) https://www.adaptimmune.com/our-company/perspectives/detail/1153/jon-silk-talks-about-our-next-generation-research
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News